For this reason, specific biomarkers have been identified for the selection of patients to submit to immunotherapy, and the efficacy of immune-related medications in solid tumors is based on the expression of specific biomarkers, e.g., PD-L1 and Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), which indicate the tumor’s susceptibility to this class of drugs. This evidence concerns the gene CD274 and neoplasm.